Given that aberrant extracellular GrB activity may be contributing to FECD pathogenesis, VTI-1002, either alone or in conjunction with antioxidant therapy may have the potential to attenuate the progression of FECD. The gene discussed is GZMB; the disease is Fuchs endothelial corneal dystrophy.